



EUROPEAN COMMISSION
RESEARCH EXECUTIVE AGENCY

Marie Skłodowska - Curie Actions



MSCA Cluster Event on Cancer Research and Innovation

Programme

18 - 19 March 2021

Online event at www.MSCA-cancer.eu

DAY 1 - Thursday 18 March

9:00 - 10:20		
Opening Session		
09:00 - 09:05	Jean-Bernard VEYRET (Research Executive Agency)	Chair and Moderator
09:05 - 09:10	Marc TACHELET (Research Executive Agency)	Welcome
09:10 - 09:20	Begoña ARANO (Research Executive Agency)	<i>Cancer research in Marie Skłodowska-Curie Actions</i>
09:20 - 09:35	John RYAN (Directorate-General for Health and Food Safety)	<i>Presentation of Europe's Beating Cancer Plan</i>
09:35 - 09:50	Christine CHOMIENNE (Université de Paris)	<i>Presentation of EU Cancer Mission</i>
09:50 - 10:05	Cathrin BRISKEN (École Polytechnique Fédérale Lausanne)	<i>Challenges and opportunities in cancer prevention</i>
10:05 - 10:20	Questions & Answers	
10:20 - 10:30		
Break		
10:30 - 12:15		
Panel 1		Diagnostic support to clinicians
10:30 - 10:35	Klaus HAUPT (Research Executive Agency)	Chair
10:35 - 10:45	Michael HUEBEL (Directorate-General for Energy)	Moderator
	Georgi SIMEONOV (Directorate-General for Energy)	Contributor
10:45 - 11:00	Martin GÖTTE (Münster University Hospital)	<i>Matrix glycans as multifunctional pathogenesis factors and therapeutic targets in cancer</i> (H2020-MSCA-RISE-2014 project 645756 - GLYCANC)
11:00 - 11:15	Valentin NICA (Italian Institute of Technology)	<i>Development of novel approaches using trimagnetic nanoparticles for intracellular hyperthermia of prostate cancer cells</i> (H2020-MSCA-COFUND-2017 project 800924 - iCARE-2)
11:15 - 11:30	Daniel ABLER (University of Applied Sciences Western)	<i>Patient-specific tumour growth model for quantification of mechanical 'markers' in malignant gliomas: Implications for treatment outcomes</i>



11:30 - 11:45	Switzerland) Zahra EL-SCHICH (Malmö University)	(H2020-MSCA-IF-2016 project 753878- GlimS) <i>Imaging and detection of tumor-associated glycan structures on tumor cells</i> (H2020-MSCA-ITN-2016 project 721297 - Glycolmaging)
11:45 - 12:15	Panel Discussion	
12:15 - 14:00	Lunch break	

14:00 - 15:45	Panel 2	Drug development and therapy
14:00 - 14:05	Monika HOLIK (Research Executive Agency)	Chair
14:05 - 14:15	Ioannis VOULDIS (Directorate-General for Research and Innovation)	Moderator
	Christoph Schultes (MERCK Group)	Contributor
14:15 - 14:30	Breandán KENNEDY (University College Dublin)	<i>Drug Discovery and Delivery NETWORK for ONcology and Eye Therapeutics</i> (H2020-MSCA-RISE-2016 project 734907 - 3D NEONET)
14:30 - 14:45	Nanasaheb THORAT (University of Oxford)	<i>Photo/magnetic stimulated nanocargos for superior cancer treatments</i> (H2020-MSCA-IF-2016 project 751903 - NANOCARGO)
14:45 - 15:00	Claus Storgaard SØRENSEN (University of Copenhagen)	<i>Targeting SYNthetic lethal interactions for new cancer treatments TRAINing network</i> (H2020-MSCA-ITN-2016 project 722729 – SYNTRAIN)
15:00 - 15:15	Oleksii RUKHLENKO (University College Dublin)	<i>Investigation of adaptive design and rewiring of Survival-Apoptosis-Mitogenic (SAM) signalling transduction network</i> (H2020-MSCA-IF-2016 project 750688 – SAMNets)
15:15 - 15:45	Panel Discussion	
15:45 - 16:00	Break	

16:00 – 17:45	Panel 3	Immunotherapy
16:00 - 16:05	Fredrik OLSSON HECTOR (Research Executive Agency)	Chair
16:05 - 16:15	Jan-Willem VAN DE LOO (Directorate-General for Research and Innovation)	Moderator
16:15 - 16:30	Jana BURKHARDT (University of Leipzig)	<i>Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy</i> (H2020-MSCA-IF-2015 project 708169 – BITCAT)
16:30 - 16:45	Edwin BREMER (University Medical Center Groningen)	<i>Immune DIREcted and Cancer-selective immunoTherapy</i> (H2020-MSCA-ITN-2018 project 813871 - I-DireCT)
16:45 - 17:00	Jara PALOMERO GORRINDO (Vall d'Hebron Institute of Oncology)	<i>In-depth profiling of neoantigen specific-lymphocyte subsets with superior traits for personalized Tcell therapies</i> (H2020-MSCA-COFUND-2017 project 801370 - BP3)
17:00 - 17:15	Rubí Misol-Há VELASCO CÁRDENAS (Albert-Ludwigs-University of Freiburg)	<i>European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry</i> (H2020-MSCA-ITN-2016 project 721358 - EN_ACTI2NG)
17:15 - 17:45	Panel Discussion	
17:45 - 18.45	Poster Session	Live chat with poster presenters of panels 1 and 2



DAY 2 - Friday 19 March

9:00 - 10:45	Panel 4	Prevention and personalized medicine
09:00 - 09:05	Monika HOLIK (Research Executive Agency)	Chair
09:05 - 09:15	Laura GARCIA IBANEZ (Directorate-General for Research and Innovation)	Moderator
09:15 - 09:30	Josep RUBERT (Wageningen University & Research)	<i>A novel integrative strategy to prevent colorectal cancer within the diet-host-microbiota triangle: from organoids to human in vivo reality</i> (H2020-MSCA-IF-2017 project 794417 – TRIANGLE)
09:30 - 09:45	Anna EROL (Medical University of Bialystok)	<i>miRNA-based biomarker development in non-small cell lung cancer for better diagnosis and prognosis</i> (H2020-MSCA-COFUND-2016 project 754432 – ImPRESS)
09:45 - 10:00	Ulrich GUENTHER (Universität zu Lübeck) Jan Jacob SCHURINGA (University Medical Center Groningen)	<i>Deciphering the Metabolism of Haematological Cancers</i> (H2020-MSCA-ITN-2015 project 675790 – HaemMetabolome)
10:00 - 10:15	Petra THALLER (Outdoor against Cancer - OAC Europe)	<i>Outdoor against Cancer: move yourself, go out and live!</i> (ERASMUS+ programme, project OAC: my goal)
10:15 - 10:45	Panel Discussion	
10:45 - 11:00	Break	
11:00 - 12:45	Panel 5	Quality of life of patients and survivors
11:00 - 11:05	Klaus HAUPT (Research Executive Agency)	Chair
11:05 - 11:15	Ciaran NICHOLL (Directorate-General Joint Research Center)	Moderator
11:15 - 11:30	Brian CAULFIELD (University College Dublin)	<i>Activating Technology for Connected Health</i> (H2020-MSCA-ITN-2016 project 722012 – CATCH)
11:30 - 11:45	Cathriona KEARNS (University College Dublin)	<i>TACTIC - Tailoring the Communication of risk To Individual breast Cancer patients</i> (H2020-MSCA-COFUND-2015 project 713279 - CAROLINE)
11:45 - 12:00	Laura FACHAL (Wellcome Sanger Institute)	<i>RADIOGENOMICS: Finding Genetic Functional Variants Through Fine Mapping</i> (H2020-MSCA-IF-2014 project 656144 – RADIOGENFF)
12:00 - 12:15	Christian OCHOA ARNEO (Catalan Institute of Oncology)	<i>Digital integration of Psychosocial Care and Health Education services</i> (EITHealth, project ONCOMMUN)
12:15 - 12:45	Panel Discussion	
12:45 - 14:30	Lunch break and poster session	Live chat with poster presenters of panels 3, 4 and 5 (12:45-13:45)



EUROPEAN COMMISSION
RESEARCH EXECUTIVE AGENCY

Marie Skłodowska - Curie Actions



14:30 - 16:00	Panel 6	Policy round table and funding opportunities
14:30 - 14:35	Fredrik OLSSON HECTOR (Research Executive Agency)	Chair
14:35 - 14:45	Claire MOREL (Directorate-General for Education, Youth, Sport and Culture)	Moderator
14:45 - 16:00	Panel discussion	
	Barbara KERSTIENS (Directorate-General for Research and Innovation)	Contributor
	Stefan SCHRECK (Directorate-General for Health and Food Safety)	Contributor
	Vanessa DEBIAIS SAINTON (Directorate-General for Education, Youth, Sport and Culture)	Contributor
	Jan-Philipp BECK (EITHealth)	Contributor
	Marisa FERNANDEZ ESTEBAN (Directorate-General for Education, Youth, Sport and Culture)	Contributor
	Pierre MEULIEN (Innovative Medicine Initiative)	Contributor
16:00 - 16:20	Break	
16:20 - 17.00	Closing Session	
16:20 - 16:25	Begoña ARANO (Research Executive Agency)	Chair
16:25 - 16:30	Poster award - winner presentation	
16:30 - 16:45	Dimitris KONTOYIANNIS (Aristotle University of Thessaloniki) Marusela OLIVERAS SALVA (Intellectual property and innovation expert)	Scientific Expert and Innovation Radar Expert remarks
16:45 - 17:00	Jean-Bernard VEYRET (Research Executive Agency)	Closing remarks and wrap-up of event

~~~~~ end of event ~~~~~



## e-Posters

In parallel to the live sessions, a **virtual poster booth** is available for the entire duration of the event. It includes the same five **Thematic Panels** with posters from all MSCA actions and EITHealth programme.

Poster presenters will be available for **live Q&A** in the following time slots:

**Poster presenters of panels 1 and 2** 18 March 2021, 17:45 – 18:45 (BE time)

**Poster presenters of panels 3, 4 and 5** 19 March 2021, 12:45 – 13:45 (BE time)

### 1. DIAGNOSTIC SUPPORT TO CLINICIANS

|            |                                                                                                                                                       |                                                                                                           |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| <b>P1</b>  | <b>FORECAST</b><br><i>Fluorescence lifetime optical biopsy system</i>                                                                                 | <b>Evgenii ZHEREBTSOV</b><br><i>University of Oulu, FINLAND</i>                                           |
| <b>P2</b>  | <b>BRIDGES</b><br><i>Bioinformatic approaches to identify and detect both disease- and drug-related genomic alterations in breast cancer patients</i> | <b>Maurizio CALLARI</b><br><i>University of Cambridge, UNITED KINGDOM</i>                                 |
| <b>P3</b>  | <b>SCARtool</b><br><i>Scattered radiation reduction tool to improve computer-aided diagnosis performance in digital breast tomosynthesis</i>          | <b>Oliver DIAZ MONTESEDOCA</b><br><i>University of Barcelona, SPAIN</i>                                   |
| <b>P4</b>  | <b>pureCTC</b><br><i>A lab-on-a-chip device for pure circulating tumor cell isolation from whole blood for cancer therapy</i>                         | <b>Sertan SUKAS</b><br><i>Eindhoven University of Technology, THE NETHERLANDS</i>                         |
| <b>P5</b>  | <b>AiPBAND</b><br><i>An Integrated Platform for Developing Brain Cancer Diagnostic Techniques</i>                                                     | <b>Yağmur YILDIZHAN</b><br><i>Katholieke Universiteit Leuven, BELGIUM</i>                                 |
| <b>P6</b>  | <b>UbiCODE</b><br><i>European Research Training to Decipher The Ub Code: identification of potential biomarkers and drug targets</i>                  | <b>Manuel S RODRIGUEZ</b><br><i>Centre national de la recherche scientifique, FRANCE</i>                  |
| <b>P8</b>  | <b>MAGNAMED</b><br><i>Novel magnetic nanostructures for medical applications</i>                                                                      | <b>Rafael MORALES</b><br><i>University of the Basque Country &amp; Basque Center for Materials, SPAIN</i> |
| <b>P9</b>  | <b>CanBioSe</b><br><i>Novel 1D photonic metal oxide nanostructures for early stage cancer detection</i>                                               | <b>Roman VITER</b><br><i>University of Latvia, LATVIA</i>                                                 |
| <b>P10</b> | <b>miRNA-DisEASY</b><br><i>microRNA biomarkers in an innovative biophotonic sensor kit for high-specific diagnosis</i>                                | <b>Simone DETASSIS</b><br><i>Optoi SRL, ITALY</i>                                                         |
| <b>P11</b> | <b>STOCKHOLM3</b><br><i>Transforming prostate cancer detection</i>                                                                                    | <b>Martin STEINBERG</b><br><i>A3P Biomedical, SWEDEN</i>                                                  |

### 2. DRUG DEVELOPMENT AND THERAPY

|            |                                                                                                                                                            |                                                                                      |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| <b>P12</b> | <b>NANOTAM</b><br><i>Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation: Targeting Tumor-Associated Macrophages</i> | <b>Fernando TORRES ANDON</b><br><i>Universidade de Santiago de Compostela, SPAIN</i> |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|



|            |                                                                                                                                                                                                          |                                                                                                       |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| <b>P13</b> | <b>BRAINHIB</b><br><i>Integrated drug discovery approach to generate brain-penetrant inhibitors of glioblastoma cell proliferation</i>                                                                   | <b>Maria Teresa VALERO GRINAN</b><br><i>The University of Edinburgh, UNITED KINGDOM</i>               |
| <b>P14</b> | <b>NANORNA_PC</b><br><i>Engineering the protein corona on RNA nanoparticles for improved nucleic acids-based therapies delivery</i>                                                                      | <b>Aurélie LACROIX</b><br><i>Sixfold Bioscience, UNITED KINGDOM</i>                                   |
| <b>P15</b> | <b>OMA</b><br><i>Optimization of Medical Accelerators</i>                                                                                                                                                | <b>Carsten P WELSCH</b><br><i>University of Liverpool and The Cockcroft Institute, UNITED KINGDOM</i> |
| <b>P16</b> | <b>HeatNMof</b><br><i>Heating triggered drug release from nanometric inorganic-metal organic framework composites</i>                                                                                    | <b>Soraya LELOUCHE</b><br><i>IMDEA Energy Institute, SPAIN</i>                                        |
| <b>P18</b> | <b>INPACT</b><br><i>Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication</i> | <b>Miguel CASTANHO</b><br><i>University of Lisbon, PORTUGAL</i>                                       |
| <b>P19</b> | <b>OXIGENATED</b><br><i>Hemoglobin based Protein Nanocarriers for Tumour Oxygenation and a more effective Photodynamic Therapy</i>                                                                       | <b>Eduardo GUIASOLA</b><br><i>CIC biomaGUNE, SPAIN</i>                                                |
| <b>P20</b> | <b>FourCmodelling</b><br><i>Conflict, Competition, Cooperation and Complexity: Using Evolutionary Game Theory to model realistic populations</i>                                                         | <b>Kateřina STAŇKOVÁ</b><br><i>Maastricht University, THE NETHERLANDS</i>                             |
| <b>P21</b> | <b>iCARE-2</b><br><i>Mechanobiology of nanoparticle-cell interactions to develop therapies against cancer</i>                                                                                            | <b>Marco CASSANI</b><br><i>St Anne's University Hospital, CZECH REPUBLIC</i>                          |
| <b>P22</b> | <b>THERADNET</b><br><i>International NETWORK for training and innovations in THERapeutic RADiation</i>                                                                                                   | <b>Martin PRUSCHY</b><br><i>University of Zurich, SWITZERLAND</i>                                     |
| <b>P23</b> | <b>PEPTOMYC</b><br><i>Reimagining cancer treatment through MYC inhibition</i>                                                                                                                            | <b>Laura SOUCEK</b><br><i>Vall d'Hebron Institute of Oncology, Peptomyc S.L., SPAIN</i>               |

### 3. IMMUNOTHERAPY

|            |                                                                                                                                            |                                                                                                                     |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| <b>P24</b> | <b>IMMUNOMARK</b><br><i>Omics integration for precision cancer immunotherapy</i>                                                           | <b>Isabel BARRAGAN</b><br><i>University Hospital of Malaga (Virgen de la Victoria), SPAIN</i>                       |
| <b>P25</b> | <b>InTheMLLrBALL</b><br><i>Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia</i> | <b>Samanta Romina ZANETTI</b><br><i>Josep Carreras Leukemia Research Institute, SPAIN</i>                           |
| <b>P27</b> | <b>THAT IS HUNT</b><br><i>Triggering Haematological Adoptive T-cell Immunotherapy Strategies by Hunting Novel T-cell receptors</i>         | <b>Eliana RUGGIERO</b><br><i>San Raffaele Hospital, ITALY</i>                                                       |
| <b>P28</b> | <b>AVITAG</b><br><i>Alphaviral Immunotherapy against Glioblastoma</i>                                                                      | <b>Miika MARTIKAINEN</b><br><i>Uppsala University, SWEDEN</i>                                                       |
| <b>P29</b> | <b>META-CAN</b><br><i>Targeting the metabolism-immune system connections in Cancer</i>                                                     | <b>Federica CAPPELLESO</b><br><i>Vlaams Instituut voor Biotechnologie – Katholieke Universiteit Leuven, BELGIUM</i> |



---

|            |                                                                                             |                                                                                         |
|------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| <b>P30</b> | <b>pHioniC</b><br><i>pH and Ion Transport in Pancreatic Cancer</i>                          | <b>Albrecht SCHWAB</b><br><i>Westfälische Wilhelms-Universität Münster,<br/>GERMANY</i> |
| <b>P31</b> | <b>T-OP</b><br><i>Training Network for Optimizing Adoptive T cell Therapy of<br/>Cancer</i> | <b>Sebastian KOBOLD</b><br><i>Klinikum der Universität München, GERMANY</i>             |
| <b>P32</b> | <b>TRAIN</b><br><i>Tribbles Research and Innovation Network</i>                             | <b>Endre KISS-TOTH</b><br><i>University of Sheffield, UNITED KINGDOM</i>                |

---

#### 4. PREVENTION AND PERSONALIZED MEDICINE

---

|            |                                                                                                                                                                                                                   |                                                                                               |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| <b>P33</b> | <b>GLIOTRAIN</b><br><i>Exploiting GLIOblastoma intractability to address European<br/>research TRAINing needs in translational brain tumour research,<br/>cancer systems medicine and integrative multi-omics</i> | <b>Alice O'FARRELL</b><br><i>RCSI University of Medicine and Health Sciences,<br/>IRELAND</i> |
| <b>P34</b> | <b>TRIM-NET</b><br><i>Training network in drug discovery targeting TRIM Ubiquitin<br/>ligases in disease</i>                                                                                                      | <b>Eleonora PAULETTO</b><br><i>Karlsruher Institut fuer Technologie, GERMANY</i>              |
| <b>P35</b> | <b>CANCERPREV</b><br><i>Innovative strategies for cancer prevention with focus on sex<br/>hormone signaling and chronic inflammation</i>                                                                          | <b>Hannes BODE</b><br><i>Institute for Molecular Medicine, FINLAND</i>                        |

---

#### 5. QUALITY OF LIFE OF PATIENTS AND SURVIVORS

---

|            |                                                                                                                                                                        |                                                                                                       |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| <b>P36</b> | <b>ElectroPros</b><br><i>Training research pioneers by utilizing and validating the<br/>promise of electroporation for minimal invasive oncological<br/>treatments</i> | <b>Prashanth Lakshmi NARASIMHAN</b><br><i>Eindhoven University of Technology, THE<br/>NETHERLANDS</i> |
| <b>P37</b> | <b>WEFight</b><br><i>Holistic health apps for chronic disease management</i>                                                                                           | <b>Julien MOUSSALLI</b><br><i>WeFight, FRANCE</i>                                                     |
| <b>P38</b> | <b>BonePainII</b><br><i>A European Training Network to Combat Bone Pain</i>                                                                                            | <b>Anne-Marie HEEGAARD</b><br><i>University of Copenhagen, DENMARK</i>                                |

---